Venetoclax for the treatment of translocation (11;14) AL amyloidosisM Hasib Sidiqi, Prashant Kapoor, Abdullah S. Al Saleh et al.|Blood Cancer Journal|2020Cited by 54
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosisSurbhi Sidana, Morie A. Gertz, M Hasib Sidiqi et al.|American Journal of Hematology|2019Cited by 52
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Shaji Kumar, Rahma Warsame et al.|American Journal of Hematology|2020Cited by 51
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Prashant Kapoor, Abdullah S. Al Saleh et al.|American Journal of Hematology|2021Cited by 35
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A. Aljama, Shaji Kumar, M Hasib Sidiqi et al.|Blood Advances|2018Cited by 32